Danislav Spassov

Dr. Danislav Spassov

Medical University of Sofia, Sofia, Sofia-Grad, Bulgaria
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in IUBMB Life
Verified
Journal Article
Open access
PDF file
DSDanislav Spassov
Danislav Spassov
RJRoland Jurecic
Roland Jurecic
Drosophila Pumilio ( Pum ) protein is a founder member of a novel family of RNA‐binding proteins, known as the PUF family. The PUF proteins constitute an evolutionarily highly conserved family of proteins present from yeast to humans and plants, and are characterized by a highly conserved C‐terminal RNA‐binding domain, composed of eight tandem repeats. The conserved biochemical features and genetic function of PUF family members have emerged from studies of model organisms. PUF proteins bind to related sequence motifs in the 3' untranslated region (3'UTR) of specific target mRNAs and repress their translation. Frequently, PUF proteins function asymmetrically to create protein gradients, thus causing asymmetric cell division and regulating cell fate specification. Thus, it was recently proposed that the primordial role of PUF proteins is to sustain mitotic proliferation of stem cells. Here we review the evolution, conserved genetic and biochemical properties of PUF family of proteins, and discuss protein interactions, upstream regulators and downstream targets of PUF proteins. We also suggest that a conserved mechanism of PUF function extends to the newly described mammalian members of the PUF family (human PUM1 and PUM2, and mouse Pum1 and Pum2 ), that show extensive homology to Drosophila Pum, and could have an important role in cell development, fate specification and differentiation. IUBMB Life, 55: 359‐366, 2003

Verified
Journal Article
Open access
PDF file
DSDanislav Spassov
Danislav Spassov
Binding affinity is a fundamental parameter in drug design, describing the strength of the interaction between a molecule and its target protein. Accurately predicting binding affinity is crucial for the rapid development of novel therapeutics, the prioritization of promising candidates, and the optimization of their properties through rational design strategies. Binding affinity is determined by the mechanism of recognition between proteins and ligands. Various models, including the lock and key, induced fit, and conformational selection, have been proposed to explain this recognition process. However, current computational strategies to predict binding affinity, which are based on these models, have yet to produce satisfactory results. This article explores the connection between binding affinity and these protein-ligand interaction models, highlighting that they offer an incomplete picture of the mechanism governing binding affinity. Specifically, current models primarily center on the binding of the ligand and do not address its dissociation. In this context, the concept of ligand trapping is introduced, which models the mechanisms of dissociation. When combined with the current models, this concept can provide a unified theoretical framework that may allow for the accurate determination of the ligands’ binding affinity.

31 July 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GEGospel Enyindah-Asonye
Gospel Enyindah-Asonye
YLYan Li
Yan Li
JRJeffrey H. Ruth
Jeffrey H. Ruth
DSDanislav Spassov
Danislav Spassov
KHKatie E. Hebron
Katie E. Hebron
FLFeng Lin
Feng Lin
Significance: The CD6 T cell surface glycoprotein regulates T cell activation, andCD6is a risk gene for autoimmune diseases including multiple sclerosis (MS). Moreover, recent work indicates that CD6 is an attractive target for the development of new therapeutic approaches to autoimmune diseases such as MS. The known ligand of CD6 is CD166 (also termed ALCAM), but CD6–CD166 interactions neither explain CD6-dependent interactions with stromal cell lineages that are critical in organ-targeted autoimmune diseases nor account for effects of CD6-targeted therapeutics in autoimmune diseases. This report definitively establishes CD318 as a second ligand of CD6 and provides evidence for the importance of CD6–CD318 interactions in autoimmune diseases that affect the central nervous system and the synovial lining of joints.


10 January 2023 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
DSDanislav Spassov
Danislav Spassov
MAMariyana Atanasova
Mariyana Atanasova
IDIrini Doytchinova
Irini Doytchinova
The salt bridge is the strongest non-covalent interaction in nature and is known to participate in protein folding, protein-protein interactions, and molecular recognition. However, the role of salt bridges in the context of drug design has remained not well understood. Here, we report that a common feature in the mechanism of inhibition of the N-myristoyltransferases (NMT), promising targets for the treatment of protozoan infections and cancer, is the formation of a salt bridge between a positively charged chemical group of the small molecule and the negatively charged C-terminus of the enzyme. Substituting the inhibitor positively charged amine group with a neutral methylene group prevents the formation of the salt bridge and leads to a dramatic activity loss. Molecular dynamics simulations have revealed that salt bridges stabilize the NMT-ligand complexes by functioning as molecular clips that stabilize the conformation of the protein structure. As such, the creation of salt bridges between the ligands and their protein targets may find an application as a valuable tool in rational drug design.